25至30岁女性宫颈上皮内瘤变2级的主动期待治疗作为替代方案:ExCIN2——一项前瞻性临床多中心队列研究
该前瞻性多中心队列研究纳入127例25至30岁、鳞柱交界完全可见且组织学确诊宫颈上皮内瘤变2级(CIN2)的女性,随访2年。2年内部分或完全消退率为72%(95%CI 63-79);HPV16阳性者消退率51%(95%CI 36-66)、进展率47%(95%CI 32-62),HPV非16型者消退率83%(95%CI 73-90)、进展率16%(95%CI 9-26),两组消退与进展差异均有统计学意义(P=.0001和P=.0002)。
要点
- 25至30岁CIN2女性2年内部分或完全消退率为72%(95%CI 63-79)。
- HPV16阳性者消退率51%、进展率47%;HPV非16型者消退率83%、进展率16%。
- 多数消退和进展发生在15个月内。
核心结论
- CIN2消退率较高,HPV16是自然病程的强决定因素。
- 25至30岁、鳞柱交界完全可见且无HPV16感染者一般应推荐主动监测15个月;HPV16阳性者应考虑立即治疗。
研究设计与样本
- 前瞻性纵向多中心临床研究,2017年2月至2021年6月在瑞典西约塔兰地区5家阴道镜门诊开展。
- 符合方案组共127例25至30岁、鳞柱交界完全可见且组织学确诊CIN2的女性。
- 随访2年,每6个月进行阴道镜检查、细胞学、HPV检测及至少2次宫颈活检,直至进展或消退。
主要发现
- 符合方案分析中,2年内部分或完全消退见于72%的患者(95%CI 63-79)。
- HPV16阳性者消退率为51%(95%CI 36-66),进展率为47%(95%CI 32-62)。
- HPV非16型组消退率为83%(95%CI 73-90),进展率为16%(95%CI 9-26)。
- 两组消退差异有统计学意义(P=.0001),进展差异亦有统计学意义(P=.0002)。
- 两组多数消退和进展均发生在15个月内。
关键数值与推荐
- 主要结局指标为HPV16阳性与HPV16阴性病例在6、12、18和24个月时的CIN2消退率。
- 次要结局为持续和进展。
临床怎么用
- 作者认为,25至30岁、鳞柱交界完全可见且无HPV16感染者一般应推荐主动监测15个月。
- 作者认为,HPV16阳性者应考虑立即治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of cervical intraepithelial neoplasia grade 2 is a clinical dilemma. Cervical intraepithelial neoplasia grade 3 is considered a cancer precursor and is always treated with excision. Most of the cervical intraepithelial neoplasia grade 1 cases regress spontaneously, and it is internationally mostly monitored with expectant management. Surgical treatment of cervical intraepithelial neoplasia entails increased risk of preterm birth in future pregnancies. Cervical intraepithelial neoplasia grade 2 in women aged under 25 years is quite well-studied; the regression rate is high and the cervical cancer risk is low. Cervical intraepithelial neoplasia grade 2 in women aged 25 years and above, in whom the risk of occult cancer is higher, has been less studied. OBJECTIVE: This study aimed to evaluate the natural course, over 2 years, of untreated cervical intraepithelial neoplasia grade 2 in women aged 25 to 30 years and its association with human papillomavirus 16. STUDY DESIGN: The study was conducted as a prospective longitudinal multicenter clinical study during February 2017 to June 2021 at 5 colposcopy clinics managing referrals after abnormal cervical screening in Region Västra Götaland, Sweden. The per protocol group comprised 127 women, aged 25 to 30 years, with fully visible squamocolumnar junction and histologically verified cervical intraepithelial neoplasia grade 2. The patients were followed up for 2 years with colposcopy, cytology, human papillomavirus tests, and at least 2 cervical biopsies every 6 months until progression or regression. The main outcome measures were the rates of regression of cervical intraepithelial neoplasia grade 2 at 6, 12, 18, and 24 months in cases with human papillomavirus 16 and those without human papillomavirus 16. The secondary outcomes were persistence and progression. RESULTS: In the per protocol analysis, partial or total regression during the 2-year period was found in 72% of patients (95% confidence interval, 63-79). In patients with human papillomavirus 16, the regression rate was 51% (95% confidence interval, 36-66) and the progression rate was 47% (95% confidence interval, 32-62). In the human papillomavirus-non-16 group, 83% (95% confidence interval, 73-90) regressed and 16% (95% confidence interval, 9-26) progressed. Most of the regression and progression in both the groups occurred within 15 months. The difference in regression between human papillomavirus 16 and human papillomavirus-non-16 cases was statistically significant (P value=.0001), as was the difference in progression (P=.0002). CONCLUSION: The regression rate of cervical intraepithelial neoplasia grade 2 is high, and human papillomavirus 16 is a strong determinant of the natural course. Patients aged 25 to 30 years with a fully visible squamocolumnar junction and without human papillomavirus 16 should generally be recommended active surveillance for 15 months, whereas immediate treatment should be considered in cases with human papillomavirus 16.
引用
- Kylebäck K, Ekeryd-Andalen A, Greppe C, et al. Active expectancy as alternative to treatment for cervical intraepithelial neoplasia grade 2 in women aged 25 to 30 years: ExCIN2-a prospective clinical multicenter cohort study. Am J Obstet Gynecol. 2022. PMID: 35777432. doi:10.1016/j.ajog.2022.06.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。